Global Favipiravir Market Strategic Research Report

Scope of the Report

Favipiravir, sold under the brand name Avigan, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections. Like the experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. It is being developed and manufactured by Toyama Chemical (Fujifilm group) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensend API for it to Zhejiang Hisun Pharmaceutical Co. of China. It became a generic drug in 2019.

The Favipiravir market has witnessed accelerated growth primarily due to the global urgency for effective antiviral therapies during outbreaks such as COVID-19. Its broad-spectrum activity against RNA viruses makes it a valuable candidate in pandemic preparedness plans. Several countries have approved Favipiravir for emergency or conditional use during viral outbreaks, boosting its visibility and adoption. Moreover, the drug's oral administration route offers ease of distribution and use, particularly in low-resource settings where intravenous treatments are less feasible. Continued investment in antiviral drug research, government stockpiling programs, and the rising incidence of emerging infectious diseases are expected to sustain demand for Favipiravir and similar oral antivirals in the foreseeable future.

Despite its potential, the Favipiravir market faces significant challenges. Clinical data regarding its efficacy for diseases beyond influenza, especially COVID-19, remains mixed, which has led to varied regulatory responses across different countries. Concerns over side effects such as teratogenicity limit its use among certain patient groups, particularly pregnant women. Additionally, the presence of more effective or better-studied antiviral drugs—like remdesivir, molnupiravir, and Paxlovid—creates intense competition in the antiviral space. Intellectual property issues and varying manufacturing standards across countries also affect the consistency of Favipiravir supply and global acceptance, complicating its market expansion.

In the global Favipiravir market, ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma are the key players. The global 5 Largest Favipiravir Players account for 70% market share by revenue. India hold a key market revenue share of the Favipiravir market which account for 73%. The classification of Favipiravir includes Brand Drug and Generic Drug. Brand Drug accounted for a share of 16% in the global Favipiravir market.

This report presents a comprehensive overview of the global Favipiravir market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Brand Drug
• Generic Drug

Segment by Application

• Influenza Viruses
• COVID-19
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Favipiravir market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Influenza Viruses, COVID-19, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact